Trial · NCT04235205
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
NCT04235205, Phase 2, Completed, Yokohama City University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease. Trials, record NCT04235205. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04235205
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
- NCT number
- NCT04235205
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 102 participants, actual
- Lead sponsor
- Yokohama City University
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
- Interventions
Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g), Elobixibat 10mg + cholestyramine powder placebo, Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g), Elobixibat placebo + cholestyramine powder placebo
- First posted
- 2020-01-21
- Last updated
- 2021-11-16
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Absolute change from baseline in serum LDL-C at Week 16 | Week 16 | Serum |
| Secondary | Absolute change from baseline to Week 16 in the liver fat fraction (%) as measured by MRI-PDFF | Week 16 | MRI-PDFF |
| Secondary | Absolute change from baseline to Week 16 in hepatic fibrosis as measured by MRE | Week 16 | MRE |
| Secondary | Change from baseline to Week 16 in ALT level | Week 16 | Serum |
| Secondary | Change from baseline to Week 16 in AST level | Week 16 | Serum |
| Secondary | Change from baseline to Week 16 in γ-GTP level | Week 16 | Serum |
| Secondary | Absolute change from baseline to Week 16 in HDL-C level | Week 16 | Serum |
| Secondary | Change from baseline to Week 16 in non HDL-C level | Week 16 | Serum |
| Secondary | Change from baseline to Week 16 in LDL-C/HDL-C ratio | Week 16 | Serum |
| Secondary | Change from baseline to Week 16 in TG level | Week 16 | Serum |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04235205
GET https://conductscience.org/api/trials/v1/NCT04235205/registered